Edition:
United States

Kamada Ltd (KMDA.TA)

KMDA.TA on Tel Aviv Stock Exchange

2,526.00ILa
25 May 2017
Change (% chg)

41.00 (+1.65%)
Prev Close
2,485.00
Open
2,492.00
Day's High
2,531.00
Day's Low
2,478.00
Volume
34,866
Avg. Vol
103,668
52-wk High
2,710.00
52-wk Low
1,401.00

KMDA.TA

Chart for KMDA.TA

About

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes... (more)

Overall

Beta: 0.30
Market Cap(Mil.): ₪916.74
Shares Outstanding(Mil.): 36.42
Dividend: --
Yield (%): --

Financials

  KMDA.TA Industry Sector
P/E (TTM): -- 14.27 17.41
EPS (TTM): -0.83 -- --
ROI: -11.40 -7.17 -5.42
ROE: -12.55 -6.63 -4.68

BRIEF-Kamada Q1 loss per share $0.11

* Kamada ltd says for 2017, continues to expect proprietary products revenues between $76 to $78 million and distributed products revenues between $22 to $24 million Source text for Eikon: Further company coverage:

May 16 2017

BRIEF-Kamada announces collaboration with Massachusetts General Hospital

* Kamada Ltd - announced a collaboration with Massachusetts General Hospital

Feb 21 2017

BRIEF-Kamada appoints Gwen Melincoff to its board of directors

* Kamada announces appointment of biopharmaceutical industry veteran, Gwen Melincoff, to its board of directors Source text for Eikon: Further company coverage:

Feb 08 2017

BRIEF-Kamada Q4 loss per share $0.05

* Kamada Ltd - reaffirms revenue guidance of $100 million for 2017

Feb 06 2017

BRIEF-Kamada announces positive scientific advice response from the European Medicines Agency

* Kamada announces positive scientific advice response from the European Medicines Agency focused on Alpha-1 antitrypsin IV for treatment of acute graft-versus-host disease

Jan 23 2017

More From Around the Web

Earnings vs. Estimates